Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bajaj HealthcareBOM:539872 -1.30%69 3-Year ROIIC % is 110.22 as of Mar. 2026, which is 591% above its 10-year median of 15.96. GuruFocus rates BOM:539872 with a GF Score™ of 69/100 and a GF Value™ of ₹408.02 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 943 Drug Manufacturers companies, Bajaj Healthcare ranks better than 90.46% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Bajaj Healthcare's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 110.22%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Bajaj Healthcare's 3-Year ROIIC % or its related term are showing as below:
BOM:539872's 3-Year ROIIC % is ranked better than 90.46% of 943
companies
in the Drug Manufacturers industry
Industry Median: 3.56
vs BOM:539872: 110.22
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Bajaj Healthcare 3-Year ROIIC % Related Terms
Bajaj Healthcare 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Bajaj Healthcare's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bajaj Healthcare's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bajaj Healthcare 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bajaj Healthcare's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Bajaj Healthcare's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Bajaj Healthcare (BOM:539872) has a 3-Year ROIIC % of 110.22 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Bajaj Healthcare and its competitors. This is 591% above median its historical median of 15.96. According to the industry distribution chart, Bajaj Healthcare ranks #90 out of 943 companies in the Drug Manufacturers industry, placing it in the top 9.5%.
Is Bajaj Healthcare's 3-Year ROIIC % too high?
Bajaj Healthcare's current 3-Year ROIIC % of 110.22 is 591% above median its 10-year median of 15.96. The Drug Manufacturers industry median 3-Year ROIIC % is 3.56. Bajaj Healthcare's value of 110.22 is 2996.1% above this industry median. Based on the distribution chart, Bajaj Healthcare ranks #90 out of 943 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Bajaj Healthcare has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bajaj Healthcare's 3-Year ROIIC % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Bajaj Healthcare ranks #90 out of 943 companies for 3-Year ROIIC %. This places Bajaj Healthcare in the top 10% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 3.56. Bajaj Healthcare's value of 110.22 is 2996.1% above this benchmark. While the company's 10-year median is 15.96 vs. the industry median of 3.56, Bajaj Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.56, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bajaj Healthcare's current 3-Year ROIIC % of 110.22 is 2996.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Bajaj Healthcare and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bajaj Healthcare's current 3-Year ROIIC % is 110.22, which is 591% above median its own 10-year median of 15.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bajaj Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Bajaj Healthcare (BOM:539872) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹408.02, compared to a current price of ₹321.90 — trading 21.1% below its estimated fair value. The current 3-Year ROIIC % is 110.22, which is 591% above median its 10-year median of 15.96 and 2996.1% above the Drug Manufacturers industry median of 3.56. Bajaj Healthcare's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Bajaj Healthcare (BOM:539872), the current 3-Year ROIIC % is 110.22 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bajaj Healthcare (BOM:539872) Overvalued in 2026?
Based on GuruFocus' analysis, Bajaj Healthcare stock appears to be undervalued.
The current stock price of ₹321.90 is trading 21.1% below its estimated GF Value™ of ₹408.02.
GuruFocus considers Bajaj Healthcare to be Modestly Undervalued.
Key valuation signals for BOM:539872:
3-Year ROIIC %: 110.22 (591% above median its 10-year median of 15.96)
GF Value™: ₹408.02 vs. price of ₹321.90 (21.1% below fair value)
Industry Position: 2996.1% above the Drug Manufacturers median (#90 of 943)
No single metric tells the full story. See the BOM:539872 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bajaj Healthcare Ltd is an India-based pharmaceutical company that manufactures Active Pharmaceutical Ingredients (APIs), Intermediates, Finished Dosage Forms, and Nutraceuticals. Its products include Intermediates, API, Formulation, and Impurities. The company derives a majority of its revenue from India.
69GF Score
Get the complete analysis for BOM:539872
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539872 has been successfully added to your 
